Brokers Offer Predictions for RNAZ Q1 Earnings

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) – Stock analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of TransCode Therapeutics in a report issued on Wednesday, December 18th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($1.48) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for TransCode Therapeutics’ current full-year earnings is ($60.73) per share. HC Wainwright also issued estimates for TransCode Therapeutics’ Q2 2025 earnings at ($1.64) EPS, Q3 2025 earnings at ($1.02) EPS and Q4 2025 earnings at ($0.78) EPS.

TransCode Therapeutics Stock Down 2.3 %

Shares of TransCode Therapeutics stock opened at $3.76 on Friday. The firm’s fifty day simple moving average is $380.38 and its 200-day simple moving average is $553.50. TransCode Therapeutics has a 12 month low of $3.21 and a 12 month high of $264.00.

Hedge Funds Weigh In On TransCode Therapeutics

A hedge fund recently raised its stake in TransCode Therapeutics stock. Sheets Smith Wealth Management raised its holdings in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) by 149.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 50,138 shares of the company’s stock after acquiring an additional 30,000 shares during the quarter. Sheets Smith Wealth Management owned 0.29% of TransCode Therapeutics worth $29,000 as of its most recent filing with the SEC.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.